|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 297.94 USD | +1.98% |
|
+4.54% | -24.78% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 844M | 1.04B | 1.83B | 2.25B | 3.71B | |||||
Total Revenues | 844M | 1.04B | 1.83B | 2.25B | 3.71B | |||||
Cost of Goods Sold, Total | 140M | 169M | 310M | 323M | 682M | |||||
Gross Profit | 704M | 869M | 1.52B | 1.92B | 3.03B | |||||
Selling General & Admin Expenses, Total | 702M | 771M | 796M | 976M | 1.21B | |||||
R&D Expenses | 711M | 883M | 1B | 1.13B | 1.32B | |||||
Other Operating Expenses, Total | 1.41B | 1.65B | 1.8B | 2.1B | 2.53B | |||||
Operating Income | -709M | -785M | -282M | -177M | 502M | |||||
Interest Expense, Total | -143M | -156M | -121M | -142M | -253M | |||||
Interest And Investment Income | 1.58M | 24.81M | 95.56M | 122M | 111M | |||||
Net Interest Expenses | -141M | -131M | -25.66M | -19.87M | -141M | |||||
Other Non Operating Income (Expenses) | -57.74M | -101M | -109M | -178M | -34.96M | |||||
EBT, Excl. Unusual Items | -908M | -1.02B | -417M | -374M | 325M | |||||
Gain (Loss) On Sale Of Investments | 55.7M | -33.31M | -16.94M | -3.02M | -2.31M | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | - | -76.59M | - | - | - | |||||
EBT, Incl. Unusual Items | -852M | -1.13B | -434M | -377M | 323M | |||||
Income Tax Expense | 680K | 4.16M | 6.72M | -99.22M | 9.4M | |||||
Earnings From Continuing Operations | -853M | -1.13B | -440M | -278M | 314M | |||||
Net Income to Company | -853M | -1.13B | -440M | -278M | 314M | |||||
Net Income - (IS) | -853M | -1.13B | -440M | -278M | 314M | |||||
Net Income to Common Incl Extra Items | -853M | -1.13B | -440M | -278M | 314M | |||||
Net Income to Common Excl. Extra Items | -853M | -1.13B | -440M | -278M | 314M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -7.2 | -9.3 | -3.52 | -2.18 | 2.39 | |||||
Basic EPS - Continuing Operations | -7.2 | -9.3 | -3.52 | -2.18 | 2.39 | |||||
Basic Weighted Average Shares Outstanding | 118M | 122M | 125M | 128M | 131M | |||||
Net EPS - Diluted | -7.2 | -9.3 | -3.52 | -2.18 | 2.33 | |||||
Diluted EPS - Continuing Operations | -7.2 | -9.3 | -3.52 | -2.18 | 2.33 | |||||
Diluted Weighted Average Shares Outstanding | 118M | 122M | 125M | 128M | 135M | |||||
Normalized Basic EPS | -4.79 | -5.22 | -2.08 | -1.83 | 1.55 | |||||
Normalized Diluted EPS | -4.79 | -5.22 | -2.08 | -1.83 | 1.51 | |||||
American Depositary Receipts Ratio (ADR) | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |||||
Supplemental Items | ||||||||||
EBITDA | -661M | -741M | -228M | -120M | 557M | |||||
EBITA | -709M | -785M | -282M | -177M | 502M | |||||
EBIT | -709M | -785M | -282M | -177M | 502M | |||||
EBITDAR | -535M | -723M | -161M | -54.47M | 632M | |||||
Total Revenues (As Reported) | 844M | 1.04B | 1.83B | 2.25B | 3.71B | |||||
Effective Tax Rate - (Ratio) | -0.08 | -0.37 | -1.55 | 26.29 | 2.91 | |||||
Current Domestic Taxes | 293K | - | 4.02M | 1.6M | 1.93M | |||||
Current Foreign Taxes | 3.15M | 5.6M | 3.42M | 5.94M | 9.67M | |||||
Total Current Taxes | 3.45M | 5.6M | 7.44M | 7.54M | 11.6M | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Deferred Foreign Taxes | -2.77M | -1.43M | -713K | -107M | -2.2M | |||||
Total Deferred Taxes | -2.77M | -1.43M | -713K | -107M | -2.2M | |||||
Normalized Net Income | -567M | -636M | -260M | -234M | 203M | |||||
Interest on Long-Term Debt | 143M | 48.37M | 14.67M | 142M | 253M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | 29.7M | 36M | |||||
General and Administrative Expenses | - | - | - | - | - | |||||
Research And Development Expense From Footnotes | 792M | 883M | 1B | 1.13B | 1.32B | |||||
Net Rental Expense, Total | 126M | 17.61M | 66.64M | 65.74M | 74.37M | |||||
Imputed Operating Lease Interest Expense | 76.45M | 9.16M | 24.41M | 27.5M | 52.62M | |||||
Imputed Operating Lease Depreciation | 49.78M | 8.45M | 42.23M | 38.24M | 21.74M | |||||
Stock-Based Comp., R&D Exp. (Total) | 68.42M | 92.16M | 97.27M | 128M | 153M | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | 97.3M | 138M | 124M | 144M | 195M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 166M | 231M | 222M | 272M | 348M |
- Stock Market
- Stocks
- ALNY Stock
- Financials Alnylam Pharmaceuticals, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















